Insilico Medicine and Takeda expanded a drug-discovery collaboration built around AI-driven candidate selection. Insilico will use its platform to identify molecules meeting predefined scientific and early development criteria, while Takeda will advance selected candidates through clinical validation using its global development capabilities. The structure reflects a common model for pairing rapid, AI-enabled early discovery with late-stage execution and regulatory pathway expertise.